The Establishment of Dendritic Cell-Tumor Fusion Vaccines for Hormone Refractory Prostate Cancer Cell

PURPOSE: Dendritic cell (DC)-based tumor vaccine is an attractive modality for the treatment of hormone-refractory prostate cancer (HRPC) because it has some efficacy and few side effects in patients with poor general conditions. The aim of this study was to establish which is the most effective DC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Beom, Park, Ho Ki, Chang, Joo Hyun, Choi, In Ho, Kim, Khae Hawn, Yoon, Sang Jin, Lee, Min Sung, Jung, Han, Kim, Choung-Soo
Formato: Texto
Lenguaje:English
Publicado: The Korean Urological Association 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855480/
https://www.ncbi.nlm.nih.gov/pubmed/20414428
http://dx.doi.org/10.4111/kju.2010.51.2.139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855480/
https://www.ncbi.nlm.nih.gov/pubmed/20414428
http://dx.doi.org/10.4111/kju.2010.51.2.139

Ejemplares similares